# EDGAR Filing Document

**Accession Number:** 0001827635
**File Stem:** 0001628280-26-027634
**Filing Date:** 2026-4
**Character Count:** 3708
**Document Hash:** 0e41663e93adfd95bb0011e723011a9a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-027634.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001628280-26-027634

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veradermics, Inc
- **CENTRAL INDEX KEY:** 0001827635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843304423
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513
- **BUSINESS PHONE:** 228.372.3376

**MAIL ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VeraDermics, Inc
- **DATE OF NAME CHANGE:** 20201008

April 27, 2026

*<u>VIA EDGAR</u>*

Division of Corporation Finance

Office of Life Sciences

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Lauren Hamill

---

| | |
|:---|:---|
| **Re:** | **Veradermics, Incorporated** |
| | **Registration Statement on Form S-1** |
| | **File No. 333-295356** |
| | **Acceleration Request** |
| | **Requested Date: April 29, 2026** |
| | **Requested Time: 4:00 P.M. Eastern Time** |

---

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), we, as representatives of the several underwriters, hereby join in the request of Veradermics, Incorporated (the "**Company**") for acceleration of the effective time of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on April 29, 2026, or at such later time as the Company or its outside counsel, Ropes & Gray LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

*[Signature Page Follows]*

------

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| JEFFERIES LLC | JEFFERIES LLC |
| LEERINK PARTNERS LLC | LEERINK PARTNERS LLC |
| CITIGROUP GLOBAL MARKETS INC. | CITIGROUP GLOBAL MARKETS INC. |
| CANTOR FITZGERALD & CO. | CANTOR FITZGERALD & CO. |
| As representatives of the underwriters | As representatives of the underwriters |
| **JEFFERIES LLC** | **JEFFERIES LLC** |
| By: | /s/ Jack Fabbri |
| Name: | Jack Fabbri |
| Title: | Managing Director |
| **LEERINK PARTNERS LLC** | **LEERINK PARTNERS LLC** |
| By: | /s/ Dan Dubin, M.D. |
| Name: | Dan Dubin, M.D. |
| Title: | Vice Chairman, Head of Biopharma Investing Banking |
| **CITIGROUP GLOBAL MARKETS INC.** | **CITIGROUP GLOBAL MARKETS INC.** |
| By: | /s/ John Whittaker |
| Name: | John Whittaker |
| Title: | Managing Director, Co-Head of NAM Biotech |
| **CANTOR FITZGERALD & CO.** | **CANTOR FITZGERALD & CO.** |
| By: | /s/ Jason Fenton |
| Name: | Jason Fenton |
| Title: | Managing Director, Co-Head Equity Capital Markets |

---

*[Signature Page to Underwriters' Acceleration Request]*